Immunotherapy最新文献

Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report. 埃夫加替莫德治疗派姆单抗诱导的心肌炎、肌炎和重症肌无力重叠综合征（IM3OS） 1例

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-13 DOI: 10.1080/1750743X.2025.2517522

Stephanie S Cobelas-Cartagena, Emilio Amigo-Otero, Victoria García-Samblas, Jesus Flores-Raposo, Silvia Rodrigo-Herrero, Juan Bayo-Calero

引用次数: 0

Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience. 纳武单抗在转移性头颈部鳞状细胞癌患者中的时间毒性：单一机构的经验。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-13 DOI: 10.1080/1750743X.2025.2518913

Michelle Bradbury, Adam Gabara, Gregory R Pond, Brandon M Meyers, Adi Kartolo

{"title":"Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience.","authors":"Michelle Bradbury, Adam Gabara, Gregory R Pond, Brandon M Meyers, Adi Kartolo","doi":"10.1080/1750743X.2025.2518913","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2518913","url":null,"abstract":"Background: Treatment of platinum-refractory recurrent and metastatic head and neck squamous cell carcinoma (r/mHNSCC) involves immune-checkpoint inhibitors. Time toxicity (TT) is an emerging metric with implications for patient quality of life and decision-making. We sought to evaluate TT associated with nivolumab in these patients.Methods: This is a retrospective single-institution review of patients with platinum-refractory r/mHNSCC seen at an academic cancer center between 1 January 2018 to 31 December 2022 in Ontario, Canada. Primary outcome is TT, defined as any number of days spent undergoing cancer-related activities.Results: Of 56 patients evaluated, median age was 63 years (33-85) and 84% were male. Median overall survival (OS) and grade 3 immune-toxicities were 7.6 months and 6.2%, respectively. Median TT was 24 days (1-109), accounting for 7.6% of OS. TT accounted for 14.9% of OS in poor responders. TT accounted for only 4-6% for patients who survived more than a year.Conclusions: Our study provides an important and underexplored patient-centered metric in TT, especially in the context of incurable HNSCC with abysmal survival outcome. Our findings suggest that TT varies significantly between responders and non-responders. Duration of TT should be discussed with patients in shared decision-making when discussing palliative nivolumab.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy. 接受免疫治疗的实体瘤患者胃肠道（GI）免疫相关不良事件的缓解策略

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-06 DOI: 10.1080/1750743X.2025.2516995

Angioletta Lasagna

引用次数: 0

Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack. 溶瘤免疫病毒治疗：在抗病毒药物的大海捞针中寻找肿瘤抗原。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-06 DOI: 10.1080/1750743X.2025.2513853

Benjamin L Kendall, Richard G Vile

{"title":"Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack.","authors":"Benjamin L Kendall, Richard G Vile","doi":"10.1080/1750743X.2025.2513853","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2513853","url":null,"abstract":"Immunovirotherapy integrates the oncolytic capabilities of viruses with the modulation of the host immune system to establish robust tumor-specific immune responses. Oncolytic viruses (OVs) are natural or engineered viruses that specifically replicate in and lyse tumor cells, triggering inflammation which recruits immune effector cells to the site of infection. These conditions theoretically synergize with immune checkpoint blockade (ICB), which aids in establishing and maintaining tumor-infiltrating CD8 T cells. However, clinical data directly confirming synergy between OV and ICB therapy is limited despite ICB becoming the standard of care for several cancer types. It has been shown that viral immunodominance may limit antitumor T-cell priming and cause the attrition of tumor-specific T cells, limiting long-term therapeutic efficacy. To overcome these barriers, precise incorporation of virally expressed or exogenously administered tumor-associated antigens (TAAs) can synchronize the expansion of both antiviral and antitumor T cells, creating optimal conditions for ICB treatment. This tripartite approach leverages our understanding of antiviral immunity to efficiently expand subdominant antitumor T cells in vivo. In this review, we dissect the fundamental paradigm of immunovirotherapy regarding antiviral inflammation and TAAs, followed by relevant combinatorial strategies employed in preclinical and clinical settings for the treatment of solid tumors.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.7,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors. 血清白蛋白-肌酐比值作为免疫检查点抑制剂治疗患者的生物标志物的预后价值

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-06-05 DOI: 10.1080/1750743X.2025.2513850

Onur Bas, Mert Tokatlı, Naciye Guduk, Dilara Erdoğan, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Sahin, Deniz Can Guven, Neyran Kertmen, Sercan Aksoy, Mustafa Erman, Şuayib Yalcin, Ömer Dizdar

{"title":"Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors.","authors":"Onur Bas, Mert Tokatlı, Naciye Guduk, Dilara Erdoğan, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Sahin, Deniz Can Guven, Neyran Kertmen, Sercan Aksoy, Mustafa Erman, Şuayib Yalcin, Ömer Dizdar","doi":"10.1080/1750743X.2025.2513850","DOIUrl":"https://doi.org/10.1080/1750743X.2025.2513850","url":null,"abstract":"Background: Albumin and creatinine are considered important for understanding patient response to immune checkpoint inhibitors (ICIs). However, numerous confounding factors complicate the interpretation of albumin and creatinine alone in clinical practice. This study aims to assess the correlation between survival outcomes and serum-albumin creatinine ratio (sACR) in patients treated with ICIs.Methods: This study was conducted on individuals who received at least three doses of ICI between 2018 and 2023. Patients were divided into two groups, sACR-High and sACR-Low, based on the median level. The relationship between sACR and survival outcomes was analyzed using a cox regression model. The relationship between sACR and early progression, late progression, and long-term benefit was analyzed using a logistic regression model.Results: Patients with lower sACR had decreased overall survival (OS) (HR: 1.42, 95% CI 1.07-1.89, p = 0.014) and progression-free survival (PFS) (HR: 1.34, 95% CI 1.08-1.66, p = 0.009). sACR was associated with early progression (HR: 1.86, 95% CI, 1.14-3.01, p = 0.012), late progression (HR: 2.06, 95 % CI 1.0-4.24, p = 0.050), and long-term benefit of ICIs (HR: 1.72, 95% CI 1.002-2.93, p = 0.049).Conclusions: Our study demonstrated that sACR could serve as an independent predictor of OS, PFS, early progression, late progression, and long-term benefit in patients treated with ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.7,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging of brain metastases treated with immune checkpoint inhibitors. 免疫检查点抑制剂治疗脑转移瘤的影像学研究。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-08 DOI: 10.1080/1750743X.2025.2501931

Imren Özdamar, Sophie H A E Derks, Astrid A M van der Veldt

引用次数: 0

Biology-driven therapies of CAR T immune effector cell-associated neurotoxicity syndrome. CAR - T免疫效应细胞相关神经毒性综合征的生物学驱动疗法。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-05-29 DOI: 10.1080/1750743X.2025.2510893

Sophie Giesler, Francesca Biavasco, Tobias Wertheimer, Robert Zeiser, Janaki Manoja Vinnakota

引用次数: 0

Dietary impacts on prostate cancer immunotherapy. 饮食对前列腺癌免疫治疗的影响。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-05-29 DOI: 10.1080/1750743X.2025.2511472

Loan D Duong, Xin Lu

{"title":"Dietary impacts on prostate cancer immunotherapy.","authors":"Loan D Duong, Xin Lu","doi":"10.1080/1750743X.2025.2511472","DOIUrl":"10.1080/1750743X.2025.2511472","url":null,"abstract":"Prostate cancer is a leading cause of cancer-related mortality in men. While early-stage disease is readily treated, advanced-stage prostate cancer has a poor survival rate and limited effective therapies. Immunotherapy has achieved significant success in other malignancies, but prostate cancer is characterized by an immunosuppressive, \"cold\" tumor microenvironment that blunts immunotherapy efficacy. Emerging evidence suggests that dietary interventions - such as ketogenic diets, methionine restriction, and bioactive compounds like white button mushroom extract - can modulate the tumor microenvironment and enhance immunotherapy responses in preclinical and early clinical studies. Additionally, specific diet-derived factors (such as the ketone body β-hydroxybutyrate) have demonstrated anti-tumor immune effects on their own, representing new avenues for combination therapy. While prior reviews have addressed diet or immunotherapy in prostate cancer independently, this review integrates these domains with the aim of offering a streamlined perspective. This brief review synthesizes recent findings on dietary modulation of prostate cancer immunity, with a focus on mechanistic insights that may be leveraged to augment immunotherapy, to suggest potential combination strategies and inform future translational efforts.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"525-536"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The complexities of PD-L1 expression as an indicator of immunotherapy outcomes. PD-L1表达的复杂性是免疫治疗结果的一个指标。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-05-05 DOI: 10.1080/1750743X.2025.2500908

Robert A Needleman, Alesha A Thai

引用次数: 0

Evaluating remibrutinib in the treatment of chronic spontaneous urticaria. 评价瑞米鲁替尼治疗慢性自发性荨麻疹的疗效。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-05-01 Epub Date: 2025-06-02 DOI: 10.1080/1750743X.2025.2510892

Agnieszka Bożek, Adam Reich

{"title":"Evaluating remibrutinib in the treatment of chronic spontaneous urticaria.","authors":"Agnieszka Bożek, Adam Reich","doi":"10.1080/1750743X.2025.2510892","DOIUrl":"10.1080/1750743X.2025.2510892","url":null,"abstract":"Chronic spontaneous urticaria (CSU) is a complex inflammatory skin condition that significantly impacts patients' quality of life. Conventional treatments, such as antihistamines, often fail to provide adequate symptom control. The next step involves administering omalizumab, a monoclonal antibody targeting IgE, however, a subset of patients may not respond to this treatment underscoring the necessity for alternative treatment options. Remibrutinib, an oral, selective inhibitor of Bruton's tyrosine kinase (BTK), has emerged as a promising therapy in CSU. BTK is vital for the activation of mast cells and basophils. The inhibitory action of remibrutinib on BTK may help alleviate CSU symptoms by addressing mast cell-mediated inflammation. Clinical trials, including Phase II and III studies, have shown promising efficacy and a favorable safety profile for remibrutinib in treating CSU. Patients experienced rapid symptom relief, with notable improvements in the Urticaria Activity Score (UAS7) concerning both itch intensity and the severity of hives. The safety profile was also commendable, with no significant treatment-related adverse events requiring therapy cessation or posing immediate health risks to patients. These results indicate that remibrutinib may become a preferred oral treatment for patients with moderate to severe CSU who do not adequately respond to standard therapies.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"479-484"},"PeriodicalIF":2.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0